N4 Pharma PLC New Patent Filing

RNS Number : 6757O

N4 Pharma PLC

04 December 2024

 

4 December 2024

N4 Pharma plc

("N4 Pharma" or the "Company")

 

New Patent Filing

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing novel RNA therapeutics usings its proprietary delivery systems, is pleased to announce it has filed a new patent for its oral anti-inflammatory Irritable Bowel Disease ("IBD") product in early pre-clinical development.

 

The orally delivered product uses the unique capabilities of the Company's Nuvec® delivery system to target the macrophage cells responsible for the inflammation associated with IBD. Each Nuvec® nanoparticle contains two separate RNA, an siRNA to inhibit the production of TNF-alpha and an mRNA to promote the body's natural anti-inflammatory defenses. By delivering these RNA together locally in the gut, the symptoms of IBD can be more readily treated.

 

The patent has been filed with the UK patent office.

 

Please visit the N4 Pharma Investor Hub to submit any questions and find more information, including an additional video by Nigel Theobald, CEO: https://investors.n4pharma.com/link/XyO8oe.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We are excited by the potential of this product as it not only addresses a strong clinical need to replace injectable TNF-alpha inhibitors and other oral solutions with significant side effects, it also showcases the key features of the Nuvec® system, namely the ability to protect the payload, target delivery to a particular cell type and load multiple RNA onto the one nanoparticle.

 

"By filing the patent, we are now able to talk in more detail to our investors and potential collaborators about this product and will shortly provide an update on the in-vitro work we have completed giving more detail regarding our approach."

 

 

For more information please contact:

 

N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director   Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	Via N4 Pharma Investor Hub Sign up at investors.n4pharma.com   https://investors.n4pharma.com/link/XyO8oe
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)	Tel: [phone]
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope	Tel: [phone]

Glossary

 

RNA: Ribonucleic acid, present in all living cells

 

mRNA: messenger RNA, whose role is to carry protein information from the DNA in a cell's nucleus to the cells cytoplasm to produce a particular protein.

 

siRNA: small interfering RNA, a short double-stranded RNA, one of whose strands can complement and inactivate a sequence mRNA to stop protein production.

 

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing unique nucleic acid based products using its patented delivery systems Nuvec® and Liptide®. Its first two products are an oral anti-inflammatory product for IBD and an siRNA to knock down MRTF-B which reduces scarring post Glaucoma surgery. As well as these it is looking to develop further oncology and gene therapy products.

 

Its novel delivery systems are also available to third parties for licensing to develop their own products in oncology, gene therapy and vaccines for upfront payments, milestone payments and ultimately royalty payments once products reach the market.

 

It is also seeking partners or investors to take its initial products into phase 1 clinical trials.

 

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDTJBRTMTIMBII